I
Ichiro Kinoshita
Researcher at Hokkaido University
Publications - 119
Citations - 9528
Ichiro Kinoshita is an academic researcher from Hokkaido University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 32, co-authored 96 publications receiving 8532 citations. Previous affiliations of Ichiro Kinoshita include National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo,Akira Inoue,Kunihiko Kobayashi,Shunichi Sugawara,Satoshi Oizumi,Hiroshi Isobe,Akihiko Gemma,Masao Harada,Hirohisa Yoshizawa,Ichiro Kinoshita,Yuka Fujita,Shoji Okinaga,Haruto Hirano,Kozo Yoshimori,Toshiyuki Harada,Takashi Ogura,Masahiro Ando,Hitoshi Miyazawa,Tomoaki Tanaka,Yasuo Saijo,Koichi Hagiwara,Satoshi Morita,Toshihiro Nukiwa +22 more
TL;DR: First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy.
Journal ArticleDOI
B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression
Jun Konishi,Koichi Yamazaki,Miyuki Azuma,Ichiro Kinoshita,Hirotoshi Dosaka-Akita,Masaharu Nishimura +5 more
TL;DR: The expression of B7-H1 on tumor cells in local areas reciprocally correlated with the number of TILs, and this may contribute to negative regulation in antitumor immune responses in non-small cell lung cancer.
Journal ArticleDOI
Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
Shigeki Chiba,Muhammad Baghdadi,Hisaya Akiba,Hironori Yoshiyama,Ichiro Kinoshita,Hirotoshi Dosaka-Akita,Yoichiro Fujioka,Yusuke Ohba,Jacob V. Gorman,John D. Colgan,Mitsuomi Hirashima,Toshimitsu Uede,Akinori Takaoka,Hideo Yagita,Masahisa Jinushi +14 more
TL;DR: Tumor-associated dendritic cells in mouse tumors and patients with cancer had high expression of TIM-3, which suppressed innate immune responses through the recognition of nucleic acids by Toll-like receptors and cytosolic sensors via a galectin-9-independent mechanism.
Journal ArticleDOI
Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells
Masahisa Jinushi,Shigeki Chiba,Hironori Yoshiyama,Kenkichi Masutomi,Ichiro Kinoshita,Hirotoshi Dosaka-Akita,Hideo Yagita,Akinori Takaoka,Hideaki Tahara +8 more
TL;DR: The pharmacological targeting of key factors derived from tumor-associated inflammation provides a unique strategy to eradicate therapy-resistant tumors by manipulating CSC activities.
Journal ArticleDOI
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
Hajime Asahina,Kohichi Yamazaki,Ichiro Kinoshita,Noriaki Sukoh,M Harada,Hiroshi Yokouchi,Takashi Ishida,Shigeaki Ogura,T. Kojima,Y Okamoto,Y Fujita,Hirotoshi Dosaka-Akita,Hiroshi Isobe,Masaharu Nishimura +13 more
TL;DR: This study showed that gefitinib is very active and well tolerated as first-line therapy for advanced NSCLC with EGFR mutations.